[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201492010A1 - Применение высокой дозы лахинимода для лечения рассеянного склероза - Google Patents

Применение высокой дозы лахинимода для лечения рассеянного склероза

Info

Publication number
EA201492010A1
EA201492010A1 EA201492010A EA201492010A EA201492010A1 EA 201492010 A1 EA201492010 A1 EA 201492010A1 EA 201492010 A EA201492010 A EA 201492010A EA 201492010 A EA201492010 A EA 201492010A EA 201492010 A1 EA201492010 A1 EA 201492010A1
Authority
EA
Eurasian Patent Office
Prior art keywords
human patient
multiple sclerosis
treating
pharmaceutically acceptable
treatment
Prior art date
Application number
EA201492010A
Other languages
English (en)
Inventor
Дэн Бар-Зохар
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492010(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201492010A1 publication Critical patent/EA201492010A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В настоящем изобретении описаны способы лечения пациента-человека, страдающего от рассеянного склероза или имеющего клинически изолированный синдром, способы лечения пациента-человека путем обеспечения нейропротекции пациенту-человеку и способы лечения пациента-человека, страдающего от рассеянного склероза или имеющего клинически изолированный синдром, путем увеличения времени до подтвержденного прогрессирования заболевания, увеличения времени до подтвержденного рецидива или уменьшения атрофии головного мозга у пациента-человека, включающий пероральное введение пациенту-человеку или субъекту суточной дозы около 1,2 мг лахинимода или его фармацевтически приемлемой соли. Заявленное изобретение также обеспечивает фармацевтическую пероральную стандартную дозированную форму около 1,2 мг лахинимода или его фармацевтически приемлемой соли и фармацевтически приемлемого носителя для применения в лечении пациента-человека, страдающего от рассеянного склероза или имеющего клинически изолированный синдром.
EA201492010A 2012-05-02 2013-05-01 Применение высокой дозы лахинимода для лечения рассеянного склероза EA201492010A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02
PCT/US2013/039090 WO2013166166A1 (en) 2012-05-02 2013-05-01 Use of high dose laquinimod for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
EA201492010A1 true EA201492010A1 (ru) 2015-06-30

Family

ID=49514859

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492010A EA201492010A1 (ru) 2012-05-02 2013-05-01 Применение высокой дозы лахинимода для лечения рассеянного склероза

Country Status (21)

Country Link
US (3) US20130303569A1 (ru)
EP (1) EP2844255A4 (ru)
JP (2) JP2015515985A (ru)
KR (1) KR20150013658A (ru)
CN (2) CN105832733A (ru)
AR (1) AR090885A1 (ru)
AU (1) AU2013256352A1 (ru)
BR (1) BR112014027010A2 (ru)
CA (1) CA2870684A1 (ru)
CL (1) CL2014002935A1 (ru)
EA (1) EA201492010A1 (ru)
HK (1) HK1206246A1 (ru)
IL (1) IL235337A0 (ru)
MX (1) MX2014013039A (ru)
PE (1) PE20150161A1 (ru)
PH (1) PH12014502447A1 (ru)
SG (1) SG11201406594UA (ru)
TW (2) TW201804997A (ru)
UY (1) UY34775A (ru)
WO (1) WO2013166166A1 (ru)
ZA (1) ZA201408820B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2961406A4 (en) * 2012-10-12 2017-01-04 Teva Pharmaceutical Industries Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
US8975279B2 (en) 2012-11-07 2015-03-10 Teva Pharmaceutical Industries, Ltd. Amine salts of laquinimod
BR112015019564A2 (pt) * 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod
AU2014236232A1 (en) 2013-03-14 2015-11-05 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
SG11201608674UA (en) * 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
CA3106772A1 (en) * 2018-07-20 2020-01-23 Merck Patent Gmbh A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
DK1797109T3 (en) * 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
DK2442651T3 (en) * 2009-06-19 2015-09-21 Teva Pharma Treatment of multiple sclerosis with laquinimod
EP2523668A1 (en) * 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
EP2766020A4 (en) * 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
BR112015019564A2 (pt) * 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod

Also Published As

Publication number Publication date
PH12014502447A1 (en) 2015-01-12
PE20150161A1 (es) 2015-02-22
AU2013256352A1 (en) 2014-11-27
CA2870684A1 (en) 2013-11-07
KR20150013658A (ko) 2015-02-05
JP2015515985A (ja) 2015-06-04
UY34775A (es) 2013-11-29
US20150265592A1 (en) 2015-09-24
JP2017222691A (ja) 2017-12-21
IL235337A0 (en) 2014-12-31
CN104284663A (zh) 2015-01-14
BR112014027010A2 (pt) 2017-06-27
CN105832733A (zh) 2016-08-10
CL2014002935A1 (es) 2015-03-06
US20160000775A1 (en) 2016-01-07
EP2844255A1 (en) 2015-03-11
MX2014013039A (es) 2015-02-04
EP2844255A4 (en) 2015-10-14
SG11201406594UA (en) 2014-11-27
ZA201408820B (en) 2016-06-29
HK1206246A1 (en) 2016-01-08
AR090885A1 (es) 2014-12-10
WO2013166166A1 (en) 2013-11-07
TW201804997A (zh) 2018-02-16
TW201347762A (zh) 2013-12-01
US20130303569A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201270041A1 (ru) Лечение рассеянного склероза лаквинимодом
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
NZ714963A (en) Compositions and methods for treating anemia
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2015515985A5 (ru)
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
EA201270205A1 (ru) Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
JP2016505050A5 (ru)
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
TW201129361A (en) Methods for treating pain
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser